FierceBiotech: ShangPharma boosts Bay Area reach for early-stage research

Venture capital firm ShangPharma Innovation is growing its life science incubator on the West Coast as it looks to help early-stage biomedical work get off the ground with more lab space.

MedCity: Is too much money being invested in oncology?

The $1 billion-plus invested in Grail is the grand example, but every week, another big deal is announced. After spending $12 billion on Kite, Gilead recently purchased Cell Design Labs for $567 million. So far in 2018, Tmunity Therapeutics brought in $100 million in Series A funding and Celgene put down $9 billion for Juno Therapeutics– and it’s only a month into the new year.

BioCentury: ShangPharma, Icahn in R&D Deal

BioWorld: Other news to note

Endpoints: AveXis wants $400M more for promising SMA gene therapy; ShangPharma partners with Icahn School of Medicine at Mount Sinai

BioSpace: ShangPharma Innovation and Icahn School of Medicine at Mount Sinai Forge Translational Research Collaboration